The Pricing Policy Mirage: Three Signals That Washington’s Drug Cost Crusade Is Reshaping Pharma Strategy Without Fixing Prices
Trump's executive orders and IRA negotiations promise relief, but branded drug prices rose 4.5% in 2024 and U.S. drugs...
respiratory biologics
AstraZeneca’s Tozorakimab Has Already Won the COPD Biologic Race — The Market Just Doesn’t Know It Yet
AstraZeneca's tozorakimab hit dual Phase III endpoints in COPD via OBERON and TITANIA, targeting a $1.68B biologic market with...
Sanofi’s Lunsekimig Just Made the Dupixent Succession Plan Legible
A bispecific nanobody hitting primary endpoints in both asthma and CRSwNP phase 2 trials isn't just a pipeline win...